Health Insurance Status, Cost-Related Medication Underuse, and Outcomes Among Diabetes Patients in Three Systems of Care

BackgroundChronically ill patients often experience difficulty paying for their medications and, as a result, use less than prescribed. ObjectivesThe objectives of this study were to determine the relationship between patients with diabetes’ health insurance coverage and cost-related medication underuse, the association between cost-related underuse and health outcomes, and the role of comorbidity in this process. Research DesignWe used a patient survey with linkage to insurance information and hemoglobin A1C (A1C) test results. Patients.We studied 766 adults with diabetes recruited from 3 Veterans Affairs (VA), 1 county, and 1 university healthcare system. Main Outcomes.Main outcomes consisted of self-reported medication underuse as a result of cost, A1C levels, symptom burden, and Medical Outcomes Study 12-Item Short-Form physical and mental functioning scores. ResultsFewer VA patients reported cost-related medication underuse (9%) than patients with private insurance (18%), Medicare (25%), Medicaid (31%), or no health insurance (40%; P <0.0001). Underuse was substantially more common among patients with multiple comorbid chronic illnesses, except those who used VA care. The risk of cost-related underuse for patients with 3+ comorbidities was 2.8 times as high among privately insured patients as VA patients (95% confidence interval, 1.2–6.5), and 4.3 to 8.3 times as high among patients with Medicare, Medicaid, or no insurance. Individuals reporting cost-related medication underuse had A1C levels that were substantially higher than other patients (P <0.0001), more symptoms, and poorer physical and mental functioning (all P <0.05). ConclusionsMany patients with diabetes use less of their medication than prescribed because of the cost, and those reporting cost-related adherence problems have poorer health. Cost-related adherence problems are especially common among patients with diabetes with comorbid diseases, although the VA’s drug coverage may protect patients from this increased risk.

[1]  G. Anderson,et al.  Out-of-pocket medical spending for care of chronic conditions. , 2001, Health affairs.

[2]  F. Lichtenberg,et al.  Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. , 2001, Health affairs.

[3]  B. Stuart,et al.  Dynamics in drug coverage of Medicare beneficiaries: finders, losers, switchers. , 2001, Health affairs.

[4]  J A Hanley,et al.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons. , 2001, JAMA.

[5]  E H Wagner,et al.  Effect of improved glycemic control on health care costs and utilization. , 2001, JAMA.

[6]  G. Kominski,et al.  Socioeconomic differences in Medicare supplemental coverage. , 2000, Health affairs.

[7]  R. Hayward,et al.  Department of Veterans Affairs' Quality Enhancement Research Initiative for Diabetes Mellitus. , 2000, Medical care.

[8]  E. Steinberg,et al.  Beyond survey data: a claims-based analysis of drug use and spending by the elderly. , 2000, Health affairs.

[9]  D. Fedele,et al.  Evaluation of diagnostic reliability of DCA 2000 for rapid and simple monitoring of HbA1c , 2000, Acta Diabetologica.

[10]  S. Soumerai,et al.  Inadequate Prescription-Drug Coverage for Medicare Enrollees — A Call to Action , 2017 .

[11]  T. Mendelson,et al.  Preventive health services and access to care for male veterans compared with their spouses. , 1998, The Western journal of medicine.

[12]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[13]  N. Ray,et al.  Economic Consequences of Diabetes Mellitus in the U.S. in 1997 , 1998, Diabetes Care.

[14]  C. Schur,et al.  Prescription drug spending: the impact of age and chronic disease status. , 1997, American journal of public health.

[15]  R. Kington,et al.  The financial burden of prescription drug use among elderly persons. , 1997, The Gerontologist.

[16]  F. Lichtenberg.  Do (more and better) drugs keep people out of hospitals? , 1996, The American economic review.

[17]  J. Ware,et al.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.

[18]  S B Soumerai,et al.  Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. , 1991, The New England journal of medicine.

[19]  E. Schor.  The Henry J. Kaiser Family Foundation. , 1990, Academic medicine : journal of the Association of American Medical Colleges.

[20]  Stephen B. Soumerai,et al.  Payment Restrictions for Prescription Drugs under Medicaid , 1987 .

[21]  S B Soumerai,et al.  Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. , 1987, The New England journal of medicine.

[22]  J. B. Ramsey,et al.  Tests for Specification Errors in Classical Linear Least‐Squares Regression Analysis , 1969 .